J&J reports Q3 2026 results, raises full-year sales and EPS guidance
Johnson & Johnson posted 5.9% reported sales growth to $25.4 billion and raised its 2026 outlook, citing regulatory and clinical progress across its portfolio.
Johnson & Johnson announced third-quarter 2026 results on October 13, 2026, reporting sales growth of 5.9% to $25.4 billion with operational growth of 6.0% and adjusted operational growth of 6.1%1. The company said strong operational performance led it to raise 2026 guidance, with estimated reported sales now projected at $101.2 billion, or 7.4% growth at the midpoint, and adjusted EPS guidance increased by $0.06 to $11.101.
The quarter included several regulatory and clinical milestones. J&J received FDA market authorization in the U.S. for its OTTAVA Robotic Surgical System1, and the FDA approved IMAAVY (nipocalimab-aahu) as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA)1. The agency also granted priority review for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as a potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer1.
On the clinical data side, the company reported that a single infusion of CARVYKTI delivered five-year treatment-free remissions in 50% of patients with early line relapsed/refractory multiple myeloma1, and separately said TECVAYLI plus TALVEY reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma1.
Within segment performance, J&J said Innovative Medicine worldwide operational sales grew 7.9%, driven largely by TREMFYA, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, ERLEADA, SPRAVATO and CAPLYTA1, while declines in older immunology and oncology products partly offset that growth. MedTech worldwide operational sales grew 2.5%, led by electrophysiology products, Shockwave, contact lenses, and trauma products in orthopaedics1.
The company also disclosed corporate actions during the quarter, including completion of its acquisition of Firefly Bio, Inc.1 and a new collaboration with Sail Biomedicines to advance in vivo CAR-T programs aimed at autoimmune disease1, as well as a proposed resolution of ovarian talc litigation1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.